Liver Disease News and Research RSS Feed - Liver Disease News and Research

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. [More]
Intervention program to help parents manage children's behaviors after being diagnosed with autism

Intervention program to help parents manage children's behaviors after being diagnosed with autism

In a first of its kind clinical trial, Debra Zand, Ph.D., and her team at Saint Louis University, will run an intervention program to help parents address and manage their children's challenging behaviors immediately after being diagnosed with autism. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
Research and planning to meet health needs of people living with HIV

Research and planning to meet health needs of people living with HIV

As effective treatments for HIV become more widely available in low- and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV. [More]
Researchers awarded $3.3 million NIH grant to study role of genetics in protecting against frailty

Researchers awarded $3.3 million NIH grant to study role of genetics in protecting against frailty

Frailty is a common condition associated with old age, characterized by weight loss, weakness, decreased activity level and reduced mobility, which together increase the risk of injury and death. Yet, not all elderly people become frail; some remain vigorous and robust well into old-age. [More]
Viewpoints: Ignagni on prices of new drugs; Sen. Johnson on the difficulty of suing a president

Viewpoints: Ignagni on prices of new drugs; Sen. Johnson on the difficulty of suing a president

Lately, there has been considerable debate about the soaring prices of specialty drugs, which are aimed at difficult-to-treat diseases. [More]

Medicaid roundup: Florida receives 3-year renewal for managed care program; Illinois limits Sovaldi

About 3 million Floridians are enrolled in the privatized program. Meanwhile, Illinois Medicaid puts limits on who is eligible for Sovaldi, an expensive hepatitis C drug, and Kansas recoups more than $28 million in Medicaid fraud. [More]
First Edition: August 4, 2014

First Edition: August 4, 2014

Today's headlines include a variety of health policy stories reflecting developments on the state level. [More]
Bacteria that aid in digestion help keep intestinal lining intact

Bacteria that aid in digestion help keep intestinal lining intact

Scientists at Albert Einstein College of Medicine of Yeshiva University have found that bacteria that aid in digestion help keep the intestinal lining intact. [More]

MUP policy for alcohol is targeted towards heaviest drinkers with cirrhosis

A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis. [More]
Study reveals new information about body clock's sway over metabolism

Study reveals new information about body clock's sway over metabolism

Much of the liver's metabolic function is governed by circadian rhythms - our own body clock - and UC Irvine researchers have now found two independent mechanisms by which this occurs. [More]
New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. [More]
First systematic analysis indicates that about 1 in 3000 donors in England have HEV

First systematic analysis indicates that about 1 in 3000 donors in England have HEV

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around 1200 HEV-containing blood components (eg, red cells, platelets, and fresh frozen plasma) are likely to be transfused every year in England. [More]
Researchers provide global genotype prevalence estimates for HCV

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature of a research paper describing the identification of a unique series of bacterial biomarkers that could provide new opportunities for the development of diagnostics and treatments for liver cirrhosis. [More]
Study: Slow walking, memory complaints may predict future dementia

Study: Slow walking, memory complaints may predict future dementia

A study involving nearly 27,000 older adults on five continents found that nearly 1 in 10 met criteria for pre-dementia based on a simple test that measures how fast people walk and whether they have cognitive complaints. [More]
Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014. [More]

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs. [More]